Navigation Links
Watson's Generic Prograf® 5 mg Receives FDA Approval
Date:7/2/2010

MORRISTOWN, N.J., July 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Tacrolimus 5 mg capsules, the generic equivalent to Astellas' Prograf® capsules. Watson intends to begin shipping the product immediately.  

Prograf ® 5 mg had total U.S. sales of approximately $108 million for the twelve months ending May 2010, according to IMS Health.  Tacrolimus capsules are indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver, kidney, or heart transplants.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31,2009 and Watson's quarterly report on Form 10-Q for the period ended March 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Prograf ® is a registered trademark of Astellas Pharma US, Inc.

(Logo:  http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100121/LA41294LOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
2. Watson Launches Generic Biaxin(R) XL
3. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
4. Generic Substitutes Less Effective/Safe Than Branded Medications in Treating Lower Urinary Tract Symptoms
5. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
6. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
7. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
8. Bundling Two Generic Low-Cost Heart Drugs Prevents Heart Attack and Stroke in Large, Diverse Population, Observational Clinical Study Shows
9. Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs
10. Perrigo Confirms Filing for Generic Version of Mens Rogaine(R) Foam
11. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... In March, 2016, Rx-360 ... free workshops across Africa ... Good Distribution Practices (GDP). Good Distribution Practice is ... are consistently stored, transported and handled under suitable conditions as ... Only a few years ago, there were few ...
(Date:5/4/2016)... Research and Markets has ... Myeloma Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Highlights 2016, provides comprehensive insights into Multiple ... Myeloma market valuations and forecast, Multiple Myeloma ...
(Date:5/4/2016)... DUBLIN , May 4, 2016 /PRNewswire/ ... the addition of the  "Global Acute Myeloid ... 2016"  report to their offering.  ... ,Global Acute Myeloid Leukemia Market and Competitive ... Acute Myeloid Leukemia pipeline products, Acute Myeloid ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 05, 2016 , ... The talus is the part ankle that ... or traffic accidents can cause the talus bone to be fractured, and a high ... a first-of-its-kind procedure using 3D printing technology, internationally renowned orthopedic surgeon Dr. Mark ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... children has donated 100 of its innovative kicking trainers to St. Jude Children’s ... The SOCKIT is a durable, lightweight rubber band designed to teach children how ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... Camas and Vancouver, WA, has announced the latest beneficiary of their ongoing ... Foundation and their Mammography Program, which provides free mammograms and diagnostic breast ...
(Date:5/4/2016)... ... May 04, 2016 , ... IsoComforter, ... the introduction of the innovative newly improved Iso-Hip Wrap. The newly designed ... plush design enhances comfort and enables the patient to enjoy the benefits of ...
(Date:5/4/2016)... ... May 04, 2016 , ... A new collaboration will ... The Duke Clinical Research Institute (DCRI) and analytics leader SAS will provide researchers worldwide ... collected by the Duke University Health System. , The DCRI and SAS share ...
Breaking Medicine News(10 mins):